At a glance
- Originator Taisho Pharmaceutical
- Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Jan 1997 Preclinical development for Cancer in Japan (unspecified route)